title: CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
abstract: Our goal was to optimize use of granulocyte colony-stimulating factor (G-CSF) after high-dose chemotherapy and autologous peripheral blood stem-cell transplantation in lymphoma patients, limiting G-CSF administration to patients infusing a suboptimal CD34(+) cell number. Of 124 consecutive patients with histologically proven Hodgkin's and non-Hodgkin's lymphoma from January 2001 to June 2004, 60 patients (group 1) given > or = 5 x 10(6)/kg CD34(+) cells received no G-CSF; 64 patients (group 2) given < or = 5 x 10(6)/kg CD34(+) cells received G-CSF from day +5 after stem-cell reinfusion. The median times to reach 0.5 x 10(9)/L and 1.0 x 10(9)/L neutrophils were, respectively, 3 and 4 d shorter in G-CSF group and this difference was statistically significant (P = 0.0014; P = 0.0001). In terms of antibiotic and antimycotic requirements, gastrointestinal toxicity, days of hospitalization, and transfusion requirements, no differences were demonstrated between the two groups. No statistically significant difference was demonstrated for the total number of febrile episodes (52 for group 1; 53 for group 2; P = 0.623) and the median number of febrile days (2 d for both groups). Myeloid reconstitution values for both groups agree with published results for autotransplanted patients treated with G-CSF from 7 to 14 d. Also, major clinical events, antibiotic, antimycotic, and transfusion requirements, and hospital stay were similar to published findings. Our data suggest that G-CSF administration can be safely optimized, used only for patients infused with a suboptimal CD34(+) cell dose.
authors.affiliation: Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milano, Italy. elisabetta.Todisco@humanitas.it
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Todisco
authors.forename: Luca
authors.initials: L
authors.lastname: Castagna
authors.forename: Barbara
authors.initials: B
authors.lastname: Sarina
authors.forename: Rita
authors.initials: R
authors.lastname: Mazza
authors.forename: Massimo
authors.initials: M
authors.lastname: Magagnoli
authors.forename: Monica
authors.initials: M
authors.lastname: Balzarotti
authors.forename: Andrea
authors.initials: A
authors.lastname: Nozza
authors.forename: Licia
authors.initials: L
authors.lastname: Siracusano
authors.forename: Inna
authors.initials: I
authors.lastname: Timofeeva
authors.forename: Antonella
authors.initials: A
authors.lastname: Anastasia
authors.forename: Monica
authors.initials: M
authors.lastname: Demarco
authors.forename: Armando
authors.initials: A
authors.lastname: Santoro
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000935:Antifungal Agents / Q000008:administration & dosage; D018952:Antigens, CD34 / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001803:Blood Transfusion; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D004363:Drug Utilization; D005260:Female; D005334:Fever / Q000453:epidemiology / Q000209:etiology; D000069585:Filgrastim; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006085:Graft Survival / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D017053:Infection Control; D007902:Length of Stay / Q000706:statistics & numerical data; D000078224:Lenograstim; D008223:Lymphoma / Q000097:blood / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D036102:Peripheral Blood Stem Cell Transplantation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D000069283:Rituximab; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000935:Antifungal Agents; D018952:Antigens, CD34; D011994:Recombinant Proteins; D003841:Deoxycytidine; D016179:Granulocyte Colony-Stimulating Factor; D000069283:Rituximab; D014747:Vinblastine; D000078224:Lenograstim; D000069585:Filgrastim; D007069:Ifosfamide